Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, ...

Artificial intelligence (AI) is no longer a distant innovation — it's now a core part of the pharmaceutical and life sciences ...

The US Supreme Court on Monday declined to review a federal appeals court decision that Merck Sharpe & Dohme Corp. couldn’t ...

That challenge, of finding or building good, useable data sets, is also one of the biggest differentiators in an increasingly ...

Merck ( MRK) is a global biopharmaceutical giant with a diversified portfolio that spans across oncology, vaccines, ...

AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILING Poster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour ...

The president wants foreign countries to pay more for drugs made in the US to help Big Pharma firms make more money abroad.

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.